Quick Answer
Tarsus Pharmaceuticals, Inc. reported Total Assets of $562.16 million for fiscal year 2025.
Tarsus Pharmaceuticals, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $562.16M | +49.1% |
| 2024 | $376.99M | +42.0% |
| 2023 | $265.49M | +16.5% |
| 2022 | $227.86M | +27.4% |
| 2021 | $178.91M | +4.0% |
| 2020 | $171.97M | +194.9% |
| 2019 | $58.32M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $534.56M | +42.1% | +8.0% |
| June 30, 2025 | $494.99M | +31.4% | -1.1% |
| March 31, 2025 | $500.75M | +43.4% | +32.8% |
| December 31, 2024 | $376.99M | +42.0% | +0.2% |
| September 30, 2024 | $376.30M | +40.2% | -0.1% |
| June 30, 2024 | $376.84M | +99.5% | +7.9% |
| March 31, 2024 | $349.28M | +65.4% | +31.6% |
| December 31, 2023 | $265.49M | +16.5% | -1.1% |
- Tarsus Pharmaceuticals, Inc. showed an increase of +49.1% in Total Assets compared to the prior fiscal year.
- Over the 2019–2025 period, Tarsus Pharmaceuticals, Inc.’s total assets has grown by 864.0% (from $58.32 million to $562.16 million).
- The most recent figure is from Tarsus Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: